Capricor Therapeutics: CAP-1002 HOPE-3 Program Update

Ғылым және технология

PPMD and Capricor Therapeutics held a community webinar on October 25, 2023 to provide an overview of the latest regulatory developments for Capricor's ongoing HOPE-3 Phase 3 study of CAP-1002, the company's cell therapy. Capricor's CEO Linda Marbán, Ph.D. and Vice President of Clinical Operations Mark Awadalla shared information about CAP-1002's clinical data trajectory and answered questions from the community.

Пікірлер: 2

  • @rameshkannarameshkanna7522
    @rameshkannarameshkanna75229 ай бұрын

    Please 🙏 explain simple terms

  • @Serenoj69

    @Serenoj69

    9 ай бұрын

    No cure, significant slowing down of aspects of the disease (seems ot be directed at the heart which in the end is the main reason for death in Duchenne). More effective when the progression of the disease is not advanced, so the younger you get this to kids the better but as of yet it is not available but it seems to be (my words, not theirs) close to coming to market. My guess (2025 +/- a year). I would like to add: beware of the enormous costs when not insured...

Келесі